{"ok":true,"entry":{"slug":"pau-darco","kind":"supplement","name":"pau d'arco","aliases":["Tabebuia impetiginosa","lapacho","taheebo"],"brands_sg":["NOW Foods","Nature's Answer","Swanson Vitamins","Nature's Way","Solaray"],"class":"botanical","tags":["immune"],"use_for":"traditional use for fever and infections — evidence is thin","use_after":"daily","use_duration":"the one human trial ran eight weeks","take_with":null,"pros":["small trial reported no serious adverse events","long traditional record in south america"],"cons":["9 of 12 in that trial reported an adverse event","no placebo arm in the one human trial","the trial used T. avellanedae, a related species"],"dose_note":"the single-arm trial gave 1050 mg/day of encapsulated Tabebuia avellanedae to twelve women for eight weeks; no dose-finding work was found","dosage":{"ul":null,"unit":"mg","fda_dv":null,"rda_ai":null,"ul_status":"none_established","population":"general adult","hsa_max_daily":null},"ul_status":"none_established","sg_class":null,"cautions":["on blood thinners — the trial tracked prothrombin times as a safety marker","the only trial enrolled healthy women aged 18-45","singapore: not listed in HSA annex A/B — that is not the same as cleared"],"clashes":[],"sources":[{"id":"epmc_pau_review2020","url":"https://europepmc.org/article/PMC/PMC7571111","label":"Tabebuia impetiginosa: a comprehensive review on traditional uses, phytochemistry, and immunopharmacological properties (Molecules, 2020)","quote":"Tabebuia impetiginosa, a plant native to the Amazon rainforest … is traditionally used for treating fever, malaria, bacterial and fungal infections, and skin diseases … Further scientific evidence is required for clinical trials on its immunopharmacological effects and safety.","accessed":"2026-08-27"},{"id":"epmc_pau_trial2022","url":"https://europepmc.org/article/PMC/PMC10032363","label":"Safety and tolerability of pau d'arco (Tabebuia avellanedae) for primary dysmenorrhea: single-arm, open-label trial (Adv Integr Med, 2022)","quote":"A single arm, open-label trial … 1050 mg/day of encapsulated Tabebuia avellanedae (Pau d'Arco) was administered to twelve healthy women aged 18-45 for eight weeks … Seventy-five percent of study participants (n = 9/12) reported an adverse event","accessed":"2026-08-27"},{"id":"hsa_prohibited","url":"https://file.go.gov.sg/hsa-chp-prohibited-restricted-ing-guidelines.pdf","label":"HSA — Guidelines on prohibited and restricted ingredients in health supplements and traditional medicines (Oct 2025), Annex A/B","quote":"The objective of this guideline is to highlight the substances of concern when used in HS and TM and is not meant to be an exhaustive list.","accessed":"2026-08-27"},{"id":"iherb_sg","url":"https://sg.iherb.com/c/pau-d-arco","label":"iHerb Singapore — Pau D'Arco category page (default best-selling order)","quote":"Pau D'Arco","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:27.496708+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}